KRAS and melanoma: MI Cancer Seek analyzes tumor DNA and RNA simultaneously from a single total nucleic acid (TNA) extraction and targets eight companion diagnostic (CDx) indications: PIK3CA alterations in breast cancer; KRAS/NRAS wild-type status in colorectal carcinoma (CRC); BRAFV600E mutations in CRC; BRAFV600E or BRAFV600K mutations in melanoma; EGFR exon19 deletions and L858R mutations in NSCLC; and microsatellite instability (MSI) status in endometrial carcinoma (not MSI-high; i.e., microsatellite stable (MSS)) and solid tumors (MSI-high) [20].